Share of biosimilars on the total marketed products in Italy in 2023, by molecule
According to the data, bevacizumab, infliximab, and rituximab were the molecules for which the share of biosimilar variations on the total marketed products was higher. More specifically, the biosimilar drugs produced from bevacizumab accounted for 98.23 percent of the total sales of this molecule, while all the other products represented 1.77 percent of the market. The graph displays the share of biosimilar drugs consumption in the total marketed products in Italy in 2023, by molecule.